Clinical Trials
39 trialsNCT05625412 2025-06-13
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT00084734 2023-08-04
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00357747 2023-08-04
AEG35156 and Docetaxel in Treating Patients With Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00372736 2023-08-04
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT01540253 2022-07-22
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Phase 1 Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT04889599 2022-01-11
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
Zhuhai Beihai Biotech Co., Ltd
Phase 3 Completed
NCT01957007 2020-09-09
A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC
Mereo BioPharma
Phase 1 Completed
NCT03089645 2020-07-27
MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.
MedImmune LLC
Phase 1 Completed
NCT01862328 2020-06-22
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
Takeda
Phase 1 Completed
NCT02146222 2019-11-18
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT02122770 2019-01-07
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00004864 2018-09-10
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT02490475 2017-05-17
A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02274610 2017-05-01
DOPNP201
Samyang Biopharmaceuticals Corporation
Phase 1 Completed
NCT00008125 2016-01-15
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
Phase 1 Completed
NCT01567163 2014-10-16
A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors
Eli Lilly and Company
Phase 2 Completed
NCT01191216 2014-07-24
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00697437 2013-12-10
Effect of Ketoconazole Inhibition of CYP3A on Urinary Excretion of Docetaxel
National University Hospital, Singapore
Phase 2 Completed
NCT01110486 2013-11-06
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT00045448 2013-05-30
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00016185 2013-04-05
Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00084786 2013-01-17
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01336582 2012-12-21
Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer
Samyang Biopharmaceuticals Corporation
Phase 1 Completed
NCT00004886 2012-09-24
MS 209 Plus Docetaxel in Treating Patients With Advanced Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Completed
NCT00251407 2012-08-09
Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00004913 2012-06-01
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Northwestern University
Phase 1 Completed
NCT00888108 2012-05-22
Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer
Abbott
Phase 1 Completed
NCT00703378 2012-03-28
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
National University Hospital, Singapore
Phase 1/2 Completed
NCT00949624 2012-01-19
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
Arog Pharmaceuticals, Inc.
Phase 1 Completed
NCT00502567 2011-07-27
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
AstraZeneca
Phase 1 Completed
NCT00401180 2011-07-08
Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer
The Cleveland Clinic
Phase 1 Completed
NCT00415116 2011-07-08
Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors
The Cleveland Clinic
Phase 1 Completed
NCT00459836 2011-03-02
PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
Proacta, Incorporated
Phase 1 Completed
NCT00253344 2010-06-11
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00004243 2010-01-13
Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
City of Hope Medical Center
Phase 1 Completed
NCT00004923 2009-08-25
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
Yale University
Phase 1/2 Completed
NCT00169520 2008-10-16
SB-715992 In Combination With Docetaxel In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed